TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Tracy T Batchelor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.